Taysha Gene Therapies Management
Management criteria checks 3/4
Taysha Gene Therapies' CEO is Sean Nolan, appointed in Dec 2022, has a tenure of 1.42 years. total yearly compensation is $1.52M, comprised of 39.4% salary and 60.6% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth $3.04K. The average tenure of the management team and the board of directors is 1.4 years and 3.3 years respectively.
Key information
Sean Nolan
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 39.4% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.0006% |
| Management average tenure | 1.4yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%
Apr 20
What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You
Mar 21Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
Mar 20Taysha: Produces Solid Data But Has Abandoned Programs
Feb 06Taysha Gene Therapies Gets A 'Thumbs Up'
Mar 07We're Hopeful That Taysha Gene Therapies (NASDAQ:TSHA) Will Use Its Cash Wisely
Mar 08Taysha and UT Southwestern Medical Center launch innovation fund in gene therapy development push
Jan 13Taysha teams up with AllStripes to advance gene therapy in rare disorder
Jan 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$600k | -US$112m |
| Sep 30 2023 | n/a | n/a | -US$214m |
| Jun 30 2023 | n/a | n/a | -US$124m |
| Mar 31 2023 | n/a | n/a | -US$133m |
| Dec 31 2022 | US$2m | US$25k | -US$166m |
| Sep 30 2022 | n/a | n/a | -US$161m |
| Jun 30 2022 | n/a | n/a | -US$186m |
| Mar 31 2022 | n/a | n/a | -US$193m |
| Dec 31 2021 | US$321k | n/a | -US$175m |
| Sep 30 2021 | n/a | n/a | -US$142m |
| Jun 30 2021 | n/a | n/a | -US$106m |
| Mar 31 2021 | n/a | n/a | -US$87m |
| Dec 31 2020 | US$457k | n/a | -US$60m |
Compensation vs Market: Sean's total compensation ($USD1.52M) is below average for companies of similar size in the US market ($USD2.40M).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
CEO
Sean Nolan (55 yo)
1.4yrs
Tenure
US$1,522,515
Compensation
Mr. Sean P. Nolan serves as Executive Chairman of Jaguar Gene Therapy, LLC. Mr. Nolan has been Chairman of the board at Taysha Gene Therapies, Inc since March 2020 and serves as its Chief Executive Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.4yrs | US$1.52m | 0.00063% $ 3.0k | |
| President | 1.4yrs | US$1.25m | 0.018% $ 88.3k | |
| CFO & Corporate Secretary | 3.8yrs | US$975.40k | 0.085% $ 408.7k | |
| Director of Corporate Communications & Investor Relations | no data | no data | no data | |
| Chief People Officer | 3.3yrs | no data | no data | |
| Chief of Staff & Technical Operations Officer | 1.3yrs | no data | no data | |
| Chief Patient Advocacy & External Affairs Officer | no data | no data | no data | |
| Chief Business Officer | no data | no data | no data | |
| Chief Scientific Advisor of UT Southwestern Gene Therapy Program | no data | no data | no data | |
| Chief Medical Advisor of UT Southwestern Gene Therapy Program | no data | no data | no data | |
| Chief Regulatory Officer | no data | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
1.4yrs
Average Tenure
55yo
Average Age
Experienced Management: TSHA's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 4.2yrs | US$1.52m | 0.00063% $ 3.0k | |
| President | 3.8yrs | US$1.25m | 0.018% $ 88.3k | |
| Independent Director | 3.8yrs | US$73.82k | 0.061% $ 294.4k | |
| Independent Director | less than a year | US$35.09k | 0.56% $ 2.7m | |
| Board Observer | less than a year | US$22.81k | 12.56% $ 60.6m | |
| Independent Scientific Advisory Board | 3.3yrs | no data | no data | |
| Independent Scientific Advisory Board | 3.3yrs | no data | no data | |
| Independent Scientific Advisory Board | 3.3yrs | no data | no data | |
| Independent Director | 3.5yrs | US$76.90k | 0% $ 0 | |
| Independent Director | less than a year | US$77.96k | no data | |
| Independent Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Independent Scientific Advisory Board | 2.6yrs | no data | no data |
3.3yrs
Average Tenure
58yo
Average Age
Experienced Board: TSHA's board of directors are considered experienced (3.3 years average tenure).